With Eli Lilly's recent acquisition of Verve Therapeutics and its PCSK9 candidate, delve into what the target represents.

BLOOMFIELD, Conn.--(BUSINESS WIRE)--Cigna (NYSE: CI) has entered into new value-based contracts with both Amgen and Sanofi/Regeneron for their PCSK9 inhibitors for commercial business. The contracts ...

Scientists think those cholesterol-lowering statins might be doing something else we didn't know about: protecting our brains ...

Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ATLANTA -- A novel PCSK9 inhibitor safely reduced LDL ...

PHILADELPHIA -- A novel anti-PCSK9 monoclonal antibody with a distinctive longer duration of action reduced cholesterol and other lipids in the phase III REMAIN-2 trial. Recaticimab showed long-term ...

Please provide your email address to receive an email when new articles are posted on . Lerodalcibep, an investigational PCSK9 inhibitor, decreased LDL cholesterol on top of existing oral agents ...

CINCINNATI (WKRC) -A new therapy could help a person lower his or her risk of having a heart attack. New research is explaining how. This new research showed that a single shot taken once a month can ...

WASHINGTON, DC — In order to be cost-effective for patients, providers, and payers, the new proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors would need to cost around $2400 per year, a mark ...

In 2023, the 7MM (seven major markets) PCSK9 inhibitors market was valued at approximately USD 2 billion, with the United States leading at around USD 900 million. That year, roughly 640,000 cases of ...

Lerodalcibep, a novel, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) by more than 50% after 1 year in patients ...

An investigational drug called lerodalcibep lowered low-density lipoprotein (LDL) cholesterol, or “bad” cholesterol, by 50% or more, a new study showed. The year-long clinical trial included people ...